Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Extrapyramidal Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Extrapyramidal Syndrome. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-000986-37 Sponsor Protocol Number: F1D-MC-HGKB Start Date*: 2004-11-26
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: An Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
    Medical condition: Schizophrenia or Schizoaffective Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) ES (Completed) SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005915-13 Sponsor Protocol Number: TRx-014-002 Start Date*: 2006-07-12
    Sponsor Name:TauRx Therapeutics PTE Ltd
    Full Title: An Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes
    Medical condition: Frontotemporal Dementia and related syndromes Prevention and reversal of tau protein aggregation is a novel approach to the treatment of patients with FTD and related syndromes and has the potent...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012267 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009235-30 Sponsor Protocol Number: CRO1250 Start Date*: 2009-12-02
    Sponsor Name:Imperial College London
    Full Title: Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS)
    Medical condition: Schizophrenia characterised by persistent negative symptoms
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000439-32 Sponsor Protocol Number: NW-3509/015/II/2019 Start Date*: 2021-04-28
    Sponsor Name:NEWRON PHARMACEUTICALS SPA
    Full Title: An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophre...
    Medical condition: Schizophrenia not responding adequately to current antipsychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10072913 Treatment-resistant schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003369-16 Sponsor Protocol Number: GWAP19030 Start Date*: 2020-06-02
    Sponsor Name:GW Research Ltd.
    Full Title: A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants with Schizophrenia Experiencing Inadequate...
    Medical condition: Schizophrenia is neurodevelopmental syndrome, results from gradual alterations in brain connectivity. Can persist for years before psychosis emerges. Individuals have a 2 to 3 fold increased risk o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000064-21 Sponsor Protocol Number: TPN-101-AGS-201 Start Date*: 2022-09-20
    Sponsor Name:Transposon Therapeutics Inc
    Full Title: A Phase 2a Study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)
    Medical condition: Aicardi-Goutières Syndrome (AGS)
    Disease: Version SOC Term Classification Code Term Level
    22.1 10010331 - Congenital, familial and genetic disorders 10083189 Aicardi-Goutieres syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000060-42 Sponsor Protocol Number: D1001066 Start Date*: 2017-03-15
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lurasidone (SM-13496) in Acutely Psychotic Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000061-23 Sponsor Protocol Number: D1001067 Start Date*: 2017-03-15
    Sponsor Name:Sunovion Pharmaceuticals Inc.
    Full Title: A 12-Week, Open-Label Extension Study of Lurasidone (SM-13496) in Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002694-22 Sponsor Protocol Number: R092670PSY3002 Start Date*: 2005-02-07
    Sponsor Name:Janssen-Cilag International N.V
    Full Title: A Randomized, Double-Blind, Parallel Group Non-inferiority Study of Flexibly Dosed Paliperidone Palmitate(25, 50, 75, 100 mg eq) Administered Every 4 weeks and Flexibly Dosed Risperdal Consta (25, ...
    Medical condition: schizophrenia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) SE (Completed) CZ (Completed) DK (Completed) EE (Completed) ES (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003536-36 Sponsor Protocol Number: ACP-103-046 Start Date*: 2018-09-03
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerativ...
    Medical condition: Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004439-36 Sponsor Protocol Number: ACP-103-047 Start Date*: 2018-09-03
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A 52-Week Open-Label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Medical condition: Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000576-16 Sponsor Protocol Number: R076477PSZ3001 Start Date*: 2012-03-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Multicenter, Double-Blind, Weight-Based, Fixed-Dose, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Extended Release Paliperidone for the Treatment of Schizo...
    Medical condition: Adolescent Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10008525 Childhood schizophrenia LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006642-34 Sponsor Protocol Number: R076477-SCH-3018 Start Date*: 2007-06-07
    Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
    Full Title: Tolerability, Safety and Treatment Response of Flexible Doses of Paliperidone ER in Acutely Exacerbated Subjects with Schizophrenia
    Medical condition: Subjects 18 years of age or older who meet the DSM-IV criteria for schizophrenia, experiencing an acute schizophrenic episode with a PANSS total score at baseline higher or equal as 70 and admitted...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001065 Acute schizophrenia episode LLT
    9.1 10001064 Acute schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001807-19 Sponsor Protocol Number: TV50717-CNS-30081 Start Date*: 2019-11-12
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)
    Medical condition: Dyskinesia in cerebral palsy (DCP)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10068804 Athetoid cerebral palsy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Prematurely Ended) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000418-13 Sponsor Protocol Number: M10-855 Start Date*: 2012-12-21
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
    Medical condition: Cognitive Deficits in Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002384-13 Sponsor Protocol Number: R076477SCH3037 Start Date*: 2008-09-17
    Sponsor Name:JANSSEN-CILAG
    Full Title: Efficacy and Tolerability of Flexible Doses of Paliperidone ER in Symptomatic Subjects with Schizophrenia with duration of illness < 10 years
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000437-41 Sponsor Protocol Number: NW-3509/014/II/2019 Start Date*: 2021-02-24
    Sponsor Name:NEWRON PHARMACEUTICALS SPA
    Full Title: A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients...
    Medical condition: Schizophrenia not responding adequately to current antipsychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10072913 Treatment-resistant schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-001168-39 Sponsor Protocol Number: SNR01-NaBen Start Date*: 2019-09-23
    Sponsor Name:SyneuRx International (Taiwan) Corp
    Full Title: An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo- Controlled, Multi-Center Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as an Add-on ...
    Medical condition: Treatment for Schizophrenia in Adolescents
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-005015-28 Sponsor Protocol Number: 1289.6 Start Date*: 2014-10-31
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment perio...
    Medical condition: Patients with schizophrenia on stable antispychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10039634 Schizophrenia residual LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001581-42 Sponsor Protocol Number: 17972A Start Date*: 2018-11-19
    Sponsor Name:H. Lunbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled, fixed-flexible-dose study of Lu AF11167 for the treatment of persistent prominent negative symptoms in patients with sc...
    Medical condition: schizophrenia with persistent prominent negative symptoms
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) LV (Prematurely Ended) HU (Completed) BG (Prematurely Ended) PL (Completed) CZ (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA